Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 15, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 1,375,000 ordinary shares of 25 pence each.
- Purchase Price: 1,444.396 pence per share.
- Treasury Shares Held: 139,663,000 shares following the transaction.
- Shares in Issue: 5,820,767,376 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a treasury stock purchase authorized by shareholders at the Annual General Meeting on May 25, 2005. The filing does not provide comparative data against prior periods for operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the share repurchase (1,375,000 shares at 1,444.396 pence).
- Confirm the updated total number of shares in issue (5,820,767,376) for earnings per share calculations.
- Review the remaining authorization for future share buybacks under the May 25, 2005 shareholder mandate.
- Note that this filing does not contain quarterly or annual financial performance data.